{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-034696","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.388036+00:00","generated_at":"2026-06-10T07:01:43.184192+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Anebulo appoints part-time CFO Daniel George replacing Sandra Gardiner effective Sept 28","bullets":["Daniel George appointed part-time CFO, principal financial and accounting officer; replaces Sandra A. Gardiner.","Compensation at $400/hour; typical schedule up to 10 hours per week, remote from Morgan Hill, CA.","Mr. George previously CFO of Lucira Health (2020-2022) and runs a consulting practice since Dec 2022.","Offer letter filed as Exhibit 10.1 includes standard at-will and arbitration provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-034696","json":"https://secwatch.observer/filing/0001493152-23-034696.json","markdown":"https://secwatch.observer/filing/0001493152-23-034696.md","text":"https://secwatch.observer/filing/0001493152-23-034696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/0001493152-23-034696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:01:43.184192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32df59de51","claim":"Sandra A. Gardiner departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/0001493152-23-034696-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a6cab2a73b","claim":"Daniel George was appointed as part-time Chief Financial Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/0001493152-23-034696-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"part-time Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}